The Parkinson’s Foundation prioritizes the needs and trust of the Parkinson’s community above all else. We believe raising awareness regarding the opportunities to participate in relevant clinical trials is important to accelerate the development of treatments and a cure. The Foundation encourages all people living with Parkinson’s disease to consider participation in a clinical trial. However, the Foundation does not recommend or endorse studies of corporate partners or other external organizations.
The following is a list of current clinical trials conducted by trusted industry partners and supporters of the Parkinson’s Foundation. The information provided below and in the links are for your convenience only and are not offered as an endorsement or recommendation to participate. For a complete list of PD-related trials, please visit the National Institutes of Health website: www.clinicaltrials.gov.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. Read more about Biogen's clinical trials here and here.
MOVES-PD (NCT02906020) is a phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of venglustat in patients with early stage PD carrying a GBA mutation. The study is composed of 2 part. Part 1 of the study is a randomized, placebo-controlled, double-blind, sequential cohort study of oral venglustat at 3 escalating doses in Parkinson disease patients ≥18 years with a heterozygous GBA mutation. The objective of Part 1 is to assess the safety, pharmacokinetics, and pharmacodynamics of venglustat in patients from Japan and ROW, and to select a venglustat dose for Part 2, the main part of the MOVES-PD study. Part 2 of the study is to determine the efficacy of venglustat in patients with early-stage PD carrying a GBA mutation when administered orally daily at the dose selected in Part 1, over a 52-week period, as compared to placebo.